Information Provided By: 
Fly News Breaks for August 3, 2015
ESRX, PTX
Aug 3, 2015 | 15:38 EDT
Brean Capital noted that Express Scripts (ESRX) added Pernix Therapeutics' (PTX) Zohydro ER to its 2016 National Preferred Formulary, which was released on July 31. The firm thinks Zohydro ER being on Express Scripts' exclusion list has been hurting the drug's uptake curve and the change to the formulary is a "major positive" for Pernix in 2016. Brean reiterates its Buy rating and $17 price target on Pernix shares.
News For PTX;ESRX From the Last 2 Days
There are no results for your query PTX;ESRX
